Search

Objective: The leaf of Withania somnifera has been used for the treatment of diarrhea without evaluation of its efficacy. This study was aimed to evaluate the antidiarrheal activity of 80% methanol extract and the solvent fraction of Withania somnifera leaf in mice. Material and Methods: The extraction was done using a cold maceration technique. The antidiarrheal activity was investigated on the castor oil-induced diarrhea, castor oil-induced gastrointestinal transit tests, and castor oil-induced enteropooling models. The mice were randomly grouped into negative control received 10ml/ kg 2% tween-80 in distilled water, positive control received 3mg/kg loperamide, and group III - V received 100 mg/kg, 200 mg/kg, and 400mg/kg of the extract orally. Results: The crude extract, aqueous, and n-butanol fractions significantly delayed the onset of diarrhea at 200mg/kg and 400mg/kg doses. All three doses of the crude extract showed significant activity on the three models (castor oil induced diarrhea, castor oil induced gastro-intestinal motility, and castor oil-induced enteropooling test), whereas the aqueous and n-butanol fractions revealed a significant result at 200mg/kg and 400mg/kg. The phytochemical screening showed that flavonoids, tannins, alkaloid, phenols, saponin, terpenoids, and steroid were presented in the crude, flavonoid, phenol, tannin, saponin, alkaloid, and steroid were possessed in aquas fraction, while the n-butanol fraction contained flavonoid, tannins, phenols, alkaloid and terpenoids, the chloroform fraction showed the presences of flavonoids, steroids and terpenoids. The acute oral toxicity test revealed that the crude extract was safe at 2000 mg/kg. Conclusion: This study demonstrated that the crude and fractions of Withania somnifera leaf has antidiarrheal activity and supports the folklore use of the plan for the treatment of diarrhea. [ABSTRACT FROM AUTHOR]

Objective: This study examined the prevalence, severity and risk factors of anaemia among adult people living with HIV attending an antiretroviral therapy centre in Woreta Primary Hospital, Woreta town, Ethiopia., Design: Hospital-based retrospective cross-sectional study., Setting: Public health facility that provides HIV care in Woreta town., Participants: A total of 289 medical records of adults living with HIV/AIDS on highly active antiretroviral therapy from February 2019 to September 2023 at government hospital were reviewed using a systematic sampling method. The data were entered using Epi-info V.7 and exported to SPSS V.23 for data analysis. The data were analysed using bivariate and then multivariate logistic regression models in order to identify variables associated with anaemia. At the 95% CI level, variables having a p value of <0.05 were deemed to be statistically significant predictors., Primary Outcome: Prevalence and severity of anaemia and its predictors among adult patients living with HIV on antiretroviral therapy in Woreta Primary Hospital., Results: The total prevalence of anaemia was 31.5% (95% CI 28.9 to 33.8). The prevalence of mild, moderate and severe anaemia was 20.42%, 10.38% and 0.70%, respectively. Predictors independently linked with anaemia were female sex (adjusted OR (AOR) 1.08), age ≥40 years (AOR 1.21), lived with HIV >10 years (AOR 2.31), CD4 counts <200 cells/µL (AOR 3.81), non-suppressed viral load (AOR 1.28), history of opportunistic infections (AOR 1.54), WHO clinical stages III and IV (AOR 1.37 and 2.23, respectively) and history of parasitic infestation (AOR 2.81)., Conclusions: A sizeable proportion of participants were found anaemic. Female sex, older age, longer periods lived with the virus, lower CD4 count, non-suppressed viral load, history of opportunistic infections, WHO clinical stages III and IV and history of parasitic infestation were the contributing factors. Therefore, to improve the anaemic status and living circumstances of patients living with HIV, immediate action on the linked factors is needed, such as monitoring for maintenance of CD4 counts >200 cells/μL and avoiding progression of HIV to the advanced WHO clinical stages, suppressed viral load, preventing opportunistic infections and parasitic infestation., Competing Interests: Competing interests: None declared., (© Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.)